Our finding that FGFR2 mutation is an independent prognostic marker in patients with early stage endometrioid endometrial cancer suggests that FGFR2 mutation testing could ultimately prove useful in the management of endometrial cancer. The gene discussed is FGFR2; the disease is endometrial cancer.